Evaluating health and nutrition in acute leukemia patients during chemotherapy
Official title: Evaluation of Physical-cognitive-functional and Nutritional Parameters in Inpatients Affected by Acute Leukemia During Intensive Chemotherapy Treatment
Run by University of Rome Tor Vergata · NCT06937554 · Data updated 2026-11-12
This study is trying to see how patients with acute leukemia feel and perform physically and mentally during chemotherapy, and how their nutrition affects their quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | University of Rome Tor Vergata Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Rome, RM) |
| Status | Recruiting |
| Started | April 10, 2025 |
| Main results expected | September 2025 |
| Study ends | September 2025 |
| Registry record updated | April 22, 2025 |
| Trial ID | NCT06937554 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 years old diagnosed with acute leukemia who are hospitalized for intensive chemotherapy.
✕Probably not a fit
Patients under 18 years old or those with medical conditions that limit their ability to participate in study-related tasks may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will assess cognitive, physical, and nutritional performance in patients with acute leukemia receiving intensive chemotherapy. Conducted at a single center, the study involves evaluations at admission, discharge, and three weeks after starting treatment. Hematologists will oversee patient management while trained rehabilitation specialists and a nutritionist will carry out the assessments. The goal is to understand how these patients perform during treatment and the impact on their quality of life.
Why it matters
Potential benefit: If successful, this study could provide insights into improving the quality of life and rehabilitation strategies for acute leukemia patients undergoing chemotherapy.
How similar studies have gone: While similar studies have explored rehabilitation in cancer patients, this specific approach focusing on acute leukemia during intensive chemotherapy is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age above 18 years * Patients affected by Acute Leukemia * Inpatients performing intensive chemotherapy * Patients with no restrictions on mobilization * Signed written informed consent in accordance with ICH/EU/GCP guidelines and national and local laws. Exclusion Criteria: * Age \<18 years * Any medical condition that the attending doctor judges as limiting to perform study related tasks
Where it's running
-
Tor Vergata university Hospital
Rome, Rm, Italy Recruiting
Study contacts
- Study coordinator: Nicola Manocchio
- Email: nicola.manocchio@uniroma2.it
- Phone: +390620908594
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Menin inhibitors in pediatric relapsed or refractory acute leukemia
This study looks at kids with relapsed or treatment-resistant acute leukemia who have specific genetic changes and are treated with menin inhibitors to see how they fare.
-
Artistic and movement activities to help anxiety in kids with ALL
Kids aged 8–13 with acute lymphoblastic leukemia test whether a 16-session art and movement program can reduce anxiety compared with standard care.
-
Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma
Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.
-
QUAIL-100 in kids and young adults after stem cell transplant with high-risk blood cancers
This study tests QUAIL-100 in pediatric and young adult patients who have high-risk acute leukemia or myelodysplastic syndrome and have already received a partially matched stem cell transplant.
-
Thiotepa-based Conditioning With Reduced Post-Transplant Cyclophosphamide for Allogeneic Stem Cell Transplant in High-Risk Blood C cancers
This phase 1 trial tests a Thiotepa, Busulfan, and Fludarabine conditioning regimen with de-escalated post-transplant cyclophosphamide to see if it can improve outcomes after allogeneic stem cell transplantation for high-risk blood cancers.
-
Menin inhibitor maintenance after allogeneic stem cell transplant
This project will try menin inhibitor maintenance to see if it helps people with acute leukemia after allogeneic stem cell transplant who have KMT2A or related gene changes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.